Bachem Holding AG (SWX:BANB)

Market Cap	5.32B +35.3%
Revenue (ttm)	695.07M +14.8%
Net Income	148.79M +23.7%
EPS	1.98 +23.8%
Shares Out	74.94M
PE Ratio	35.77
Forward PE	28.69
Dividend	0.90 (1.24%)
Ex-Dividend Date	May 4, 2026

Volume	169,475
Open	72.70
Previous Close	72.55
Day's Range	70.20 - 74.00
52-Week Range	48.52 - 83.25
Beta	0.78
Analysts	Buy
Price Target	78.80 (+10.99%)
Earnings Date	Jul 30, 2026

About Bachem Holding AG

Bachem Holding AG, together with its subsidiaries, provides products for research, clinical development, and commercial application to pharmaceutical and biotechnology companies worldwide. It engages in the development, production, and regulatory support of peptide active pharmaceutical ingredients, such as peptide and oligonucleotide new chemical entities (NCEs). The company also offers commercial NCEs and generics; and project management, quality and regulatory, analytical, good manufacturing practice production, research grade production, an...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1971
• Employees: 2,595
• Stock Exchange: SIX Swiss Exchange
• Ticker Symbol: BANB

Financial Performance

In 2025, Bachem Holding AG's revenue was 695.07 million, an increase of 14.84% compared to the previous year's 605.26 million. Earnings were 148.79 million, an increase of 23.74%.

Analyst Summary

According to 10 analysts, the average rating for BANB stock is "Buy." The 12-month stock price target is CHF 78.80, which is an increase of 10.99% from the latest price.

Price Target

CHF 78.80

(10.99% upside)

Analyst Consensus: Buy